GlassScriptPhysician profile
Susan M Danek
NPI 1265572499
$15,522.69
in general payments reported to CMS, 2019-2025
44 companies · $2,141 in 2025
The $2,141 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,679 · 2020: $1,964 · 2021: $1,994 · 2022: $1,949 · 2023: $2,227 · 2024: $2,567 · 2025: $2,141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,926 · Education: $10.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,925.62 |
| Education | $10.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,867.80 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $1,849.16 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $1,180.50 | 2019-2025 | Vraylar, Ubrelvy, Viberzi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,156.12 | 2019-2025 | Jardiance, Tradjenta, Combivent Respimat |
| Amgen INC. | $1,110.50 | 2019-2025 | Otezla, Repatha, Repatha |
| Novo Nordisk INC | $956.39 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $571.78 | 2021-2024 | |
| Medtronic, INC. | $555.75 | 2023-2025 | Intellis Adaptivestim, Vanta Adaptivestim |
| Janssen Pharmaceuticals, INC | $526.40 | 2019-2024 | Xarelto |
| Lilly USA, LLC | $524.85 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $455.49 | 2019-2025 | |
| Amarin Pharma, INC. | $449.55 | 2019-2021 | |
| Esperion Therapeutics, INC. | $385.90 | 2020-2025 | Nexletol |
| Novartis Pharmaceuticals Corporation | $343.93 | 2022-2024 | |
| Abbott Laboratories | $309.90 | 2022-2025 | Freestyle Libre 3 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $285.02 | 2019-2024 | Livalo, Seglentis, Zoryve |
| Eisai INC. | $222.16 | 2020-2025 | |
| Allergan, INC. | $199.28 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $189.51 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $156.45 | 2021-2025 | Rexulti, Abilify Asimtufii |
| Sanofi-Aventis U.S. LLC | $152.40 | 2019-2022 | |
| Horizon Therapeutics Plc | $123.82 | 2019-2020 | |
| Lundbeck LLC | $96.37 | 2024-2025 | Rexulti |
| Idorsia Pharmaceuticals US INC | $95.35 | 2023 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $94.31 | 2019-2022 | |
| Therapeuticsmd, INC. | $90.99 | 2019-2021 | |
| Seqirus USA INC | $69.78 | 2021-2023 | Flucelvax Quadrivalent |
| Intra-Sana Laboratories | $64.14 | 2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Astellas Pharma US INC | $56.55 | 2019-2024 | Veozah |
| Sumitomo Pharma America, INC. | $56.18 | 2024-2025 | Gemtesa |
| Verona Pharma, INC. | $32.62 | 2025 | Ohtuvayre |
| Mannkind Corporation | $31.24 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.27 | 2019 | |
| Biogen, INC. | $28.09 | 2024 | Leqembi |
| Phathom Pharmaceuticals, INC. | $25.07 | 2024 | Voquezna |
| Biohaven Pharmaceutical Holding Company LTD. | $24.95 | 2022 | |
| Vision Quest Industries INC. | $23.60 | 2024 | Bionicare Align Prefab R |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.04 | 2024 | Xifaxan |
| Edwards Lifesciences Corporation | $22.90 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.39 | 2024 | Caplyta |
| Antares Pharma, INC. | $19.19 | 2019 | |
| Exact Sciences Corporation | $17.38 | 2025 | Cologuard Collection Kit |
| Tactile Systems Technology INC | $15.47 | 2020 | |
| Sanofi Pasteur INC. | $14.15 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Danek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.